SCHEMBL2800907

SCHEMBL2800907

CCOC(=O)c1cnn2c(NCc3ccccc3)c(C(=O)N3CCC(c4ccc(Cl)cc4)CC3)cnc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNA2 P20248 1/20 0.54
CDK2 P24941 1/20 0.54
MAPT P10636 1/20 0.45
ADORA1 P30542 4/20 0.42
NPSR1 Q6W5P4 3/20 0.42
RAB9A P51151 3/20 0.42
ADORA3 P0DMS8 2/20 0.42
ADORA2A P29274 2/20 0.42
ADORA2B P29275 2/20 0.42
LMNA P02545 3/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
NPC1 O15118 2/20 0.42
POLB P06746 1/20 0.42
CCR1 P32246 5/20 0.42
ALDH1A1 P00352 2/20 0.42
PDE4B Q07343 1/20 0.42
MEN1 O00255 1/20 0.42
GAA P10253 1/20 0.42
KMT2A Q03164 1/20 0.42
TP53 P04637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2801294 0.91 CCNA2 (0.46) CCNA2CDK2MAPTADORA1NPSR1
SCHEMBL2801054 0.90 CCR1 (0.45) CCNA2CDK2SMN1; SMN2CCR1TP53
SCHEMBL2800801 0.87 ADORA1 (0.45) CCNA2CDK2MAPTADORA1NPSR1
SCHEMBL2800864 0.86 CCR1 (0.42) SMN1; SMN2CCR1TP53THRBENPP2
SCHEMBL2798414 0.85 STAT6 (0.43) MAPTADORA1RAB9AADORA3ADORA2A
SCHEMBL2800947 0.85 ADORA1 (0.46) CCNA2CDK2MAPTADORA1NPSR1
SCHEMBL2800936 0.84 STAT6 (0.42) ADORA1ADORA3ADORA2APOLBALDH1A1
SCHEMBL2801694 0.83 CCNA2 (0.44) CCNA2CDK2MAPTADORA1NPSR1
SCHEMBL2801075 0.83 KDM4E (0.48) MAPTADORA1NPSR1RAB9ALMNA
SCHEMBL2800838 0.82 CHRM4 (0.43) MAPTRAB9AADORA3ADORA2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2206714-B1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES KYOWA HAKKO KIRIN CO LTD (JP) 2015-01-21 EP disclosed
US-8729264-B2 Agent for prevention and/or treatment of skin diseases KYOWA HAKKO KIRIN CO., LTD. (JP) 2014-05-20 US disclosed
US-20100256134-A1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-10-07 US disclosed
EP-2206714-A1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES Kyowa Hakko Kirin Co., Ltd. (JP) 2010-07-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256134-A1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES TYR, CUTA, SERPINB1 CCNA2 2900/4885CDK2 3692/4885MAPT 2533/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.